FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:93-94 July 5, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Before iron was used as an adjunct to erythropoietic stimulatory therapy in patients undergoing hemodialysis, parenteral iron was considered to be dangerous. High-molecular-weight iron dextran (Imferon [Fisons], which is no longer manufactured) was the only product available and was associated with anaphylaxis. Nonetheless, marked improvements in hemoglobin responsiveness¹ resulted in the extensive use of high-molecular-weight iron dextran in nephrology. In the mid-1990s, two events changed the prescribing practices of nephrologists. First, high-molecular-weight iron dextran was removed from the market, and subsequently, low-molecular-weight iron dextran (InFed [Watson]) was released. Low-molecular-weight iron dextran was the standard of care for . . . [Full Text of this Article]

This article has been cited by other articles:

• Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., Henry, D. H. (2008). High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?. J. Am. Soc. Nephrol. 19: 833-834 [Full Text]